Lantheus Holdings, Inc. (NASDAQ:LNTH) Receives $126.00 Average Target Price from Brokerages

Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) have earned a consensus recommendation of “Moderate Buy” from the nine research firms that are currently covering the firm, MarketBeat reports. One analyst has rated the stock with a hold rating and eight have given a buy rating to the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $126.00.

A number of equities research analysts recently weighed in on LNTH shares. Redburn Atlantic initiated coverage on shares of Lantheus in a research note on Tuesday, September 3rd. They set a “buy” rating and a $175.00 price objective on the stock. Truist Financial reduced their price target on shares of Lantheus from $141.00 to $135.00 and set a “buy” rating for the company in a research note on Thursday, August 1st. B. Riley increased their price objective on shares of Lantheus from $105.00 to $146.00 and gave the company a “buy” rating in a report on Thursday, July 25th. JMP Securities dropped their target price on Lantheus from $130.00 to $125.00 and set a “market outperform” rating on the stock in a report on Thursday, August 1st. Finally, Leerink Partners increased their price target on Lantheus from $106.00 to $127.00 and gave the company an “outperform” rating in a research note on Thursday, July 11th.

Insider Buying and Selling at Lantheus

In other news, Director Gerard Ber sold 15,500 shares of the firm’s stock in a transaction on Monday, August 12th. The stock was sold at an average price of $96.48, for a total transaction of $1,495,440.00. Following the completion of the sale, the director now directly owns 21,221 shares of the company’s stock, valued at approximately $2,047,402.08. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In other news, CAO Andrea Sabens sold 341 shares of the business’s stock in a transaction that occurred on Monday, July 15th. The shares were sold at an average price of $123.15, for a total transaction of $41,994.15. Following the sale, the chief accounting officer now owns 62,216 shares in the company, valued at $7,661,900.40. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Gerard Ber sold 15,500 shares of the company’s stock in a transaction that occurred on Monday, August 12th. The shares were sold at an average price of $96.48, for a total transaction of $1,495,440.00. Following the completion of the sale, the director now owns 21,221 shares of the company’s stock, valued at approximately $2,047,402.08. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 40,852 shares of company stock valued at $3,922,001. Corporate insiders own 1.50% of the company’s stock.

Hedge Funds Weigh In On Lantheus

Several institutional investors and hedge funds have recently added to or reduced their stakes in LNTH. UMB Bank n.a. grew its holdings in shares of Lantheus by 161.4% during the first quarter. UMB Bank n.a. now owns 400 shares of the medical equipment provider’s stock valued at $25,000 after buying an additional 247 shares in the last quarter. GAMMA Investing LLC lifted its position in shares of Lantheus by 184.1% in the second quarter. GAMMA Investing LLC now owns 321 shares of the medical equipment provider’s stock worth $26,000 after purchasing an additional 208 shares in the last quarter. Principal Securities Inc. acquired a new stake in shares of Lantheus during the fourth quarter worth approximately $28,000. Fidelis Capital Partners LLC purchased a new position in Lantheus during the first quarter valued at approximately $34,000. Finally, FinTrust Capital Advisors LLC increased its stake in Lantheus by 53.6% in the 1st quarter. FinTrust Capital Advisors LLC now owns 665 shares of the medical equipment provider’s stock valued at $41,000 after buying an additional 232 shares during the period. 99.06% of the stock is currently owned by hedge funds and other institutional investors.

Lantheus Trading Up 1.5 %

Lantheus stock opened at $105.55 on Wednesday. Lantheus has a 52-week low of $50.20 and a 52-week high of $126.89. The company has a quick ratio of 4.41, a current ratio of 4.68 and a debt-to-equity ratio of 0.55. The firm has a market capitalization of $7.33 billion, a price-to-earnings ratio of 16.11 and a beta of 0.50. The firm has a 50-day moving average price of $104.37 and a two-hundred day moving average price of $82.38.

Lantheus (NASDAQ:LNTH) last issued its quarterly earnings data on Wednesday, July 31st. The medical equipment provider reported $1.61 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.68 by ($0.07). The business had revenue of $394.10 million during the quarter, compared to the consensus estimate of $382.12 million. Lantheus had a return on equity of 48.36% and a net margin of 29.80%. The business’s quarterly revenue was up 22.5% compared to the same quarter last year. During the same period last year, the company earned $1.40 earnings per share. Sell-side analysts expect that Lantheus will post 5.99 earnings per share for the current year.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.